Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

被引：66

作者：

Gill, Christopher J. ^{[1
]}

Baxter, Roger ^{[2
]}

Anemona, Alessandra ^{[1
]}

Ciavarro, Giuseppe L. ^{[1
]}

Dull, Peter M. ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost, Cambridge, MA USA

[2] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA

来源：

HUMAN VACCINES | 2010年 / 6卷 / 11期

关键词：

meningococcal disease; CRM-197; Menveo; Menactra; conjugate vaccine; Neisseria meningitidis; BACTERICIDAL ANTIBODY-ACTIVITY; NEISSERIA-MENINGITIDIS; UNITED-KINGDOM;

D O I：

10.4161/hv.6.11.12849

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo (R) (MenACWY-CRM; Novartis) or Menactra (R) (MCV4) (Sanofi Pasteur). The proportion of subjects with hSBA titers >= 8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.

引用

收藏

页码：881 / 887

页数：7

相关论文

共 16 条

[1]

Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention, 2009, MMWR-MORBID MORTAL W, V58, P1042

[2] Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom [J].

Auckland, Cressida ;

Gray, Stephen ;

Borrow, Ray ;

Andrews, Nick ;

Goldblatt, David ;

Ramsay, Mary ;

Miller, Elizabeth .

JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12) :1745-1752

[3] Meningococcal surrogates of protection - serum bactericidal antibody activity [J].

Borrow, R ;

Balmer, P ;

Miller, E .

VACCINE, 2005, 23 (17-18) :2222-2227

[4] Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom [J].

Borrow, R ;

Goldblatt, D ;

Finn, A ;

Southern, J ;

Ashton, L ;

Andrews, N ;

Lal, G ;

Riley, C ;

Rahim, R ;

Cartwright, K ;

Allan, G ;

Miller, E .

INFECTION AND IMMUNITY, 2003, 71 (10) :5549-5555

[5] Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005 [J].

Ceyhan, Mehmet ;

Yildirim, Inci ;

Balmer, Paul ;

Riley, Christine ;

Laher, Gouri ;

Andrews, Nick ;

Borrow, Ray ;

Kurt, Nese ;

Turgut, Mehmet ;

Aydogan, Aysel ;

Ecevit, Cigdem ;

Uysal, Gulnar ;

Schultze, Viola .

VACCINE, 2007, 25 (41) :7233-7237

[6] Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease [J].

Frasch, Carl E. ;

Borrow, Ray ;

Donnelly, John .

VACCINE, 2009, 27 :B112-B116

[7] HUMAN IMMUNITY TO MENINGOCOCCUS .I. ROLE OF HUMORAL ANTIBODIES [J].

GOLDSCHNEIDER, I ;

GOTSCHLICH, EC ;

ARTENSTEIN, MS .

JOURNAL OF EXPERIMENTAL MEDICINE, 1969, 129 (06) :1307-+

[8] Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease [J].

Granoff, Dan M. .

VACCINE, 2009, 27 :B117-B125

[9] Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents [J].

Jackson, Lisa A. ;

Baxter, Roger ;

Reisinger, Keith ;

Karsten, Annette ;

Shah, Jina ;

Bedell, Lisa ;

Dull, Peter M. .

CLINICAL INFECTIOUS DISEASES, 2009, 49 (01) :E1-E10

[10] Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays [J].

Maslanka, SE ;

Gheesling, LL ;

Libutti, DE ;

Donaldson, KBJ ;

Harakeh, HS ;

Dykes, JK ;

Arhin, FF ;

Devi, SJN ;

Frasch, CE ;

Huang, JC ;

KrizKuzemenska, P ;

Lemmon, RD ;

Lorange, M ;

Peeters, CCAM ;

Quataert, S ;

Tai, JY ;

Carlone, GM ;

Mills, EL ;

Ashton, FE ;

Diepevaen, J ;

Bielecki, J ;

Bybel, M ;

Cloutier, M ;

Poolman, JT .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (02) :156-167